Chloroquine hydrochloride
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1949
- First approval year
- 1949
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Chloroquine hydrochloride
- Molecular weight
- 392.8
- Structure (SMILES)
- CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.Cl.Cl
- aralen hydrochloride
- Aralen hydrochloride
- 1 4 pentanediamine n sup 4 7 chloro 4 quinolinyl n sup 1 n sup 1 diethyl dihydrochloride
- 1,4-PENTANEDIAMINE, N(SUP 4)-(7-CHLORO-4-QUINOLINYL)-N(SUP 1),N (SUP 1)-DIETHYL-, DIHYDROCHLORIDE
- 7 chloro 4 4 diethylamino 1 methylbutyl amino quinoline dihydrochloride
- 7-(Chloro-4-[[4-diethylamino)-1-methylbutyl]amino]quinoline dihydrochloride
- chloroquine hcl
- Chloroquine hcl
- chloroquine hydrochloride
- Chloroquine hydrochloride
- CHLOROQUINE HYDROCHLORIDE [MART.]
- CHLOROQUINE HYDROCHLORIDE [ORANGE BOOK]
- CHLOROQUINE HYDROCHLORIDE [USP IMPURITY]
- CHLOROQUINE HYDROCHLORIDE [VANDF]
- Chloroquine hydrochloride [WHO-DD]
- chloroquine hydrochloride mart
- chloroquine hydrochloride orange book
- chloroquine hydrochloride usp impurity
- chloroquine hydrochloride vandf
- chloroquine hydrochloride who dd
- CAS registry numbers
- 3545-67-3
- ChEMBL ID
- CHEMBL4297165
- InChIKey
- PCFGECQRSMVKCC-UHFFFAOYSA-N
- PubChem compound IDs
- 83820
- FDA ingredient codes (UNII)
- NT0J0815S5
- 203119
- 451796
- Applicant
- SANOFI AVENTIS US
- Approval date
- 31 Oct 1949
- Application number
- NDA006002
- First in class
- No
- Orphan designation
- No
- Availability
- discontinued
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- Ferriprotoporphyrin IX binding agent
- Action type
- BINDING_AGENT
- Target
- Ferriprotoporphyrin IX
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Lupus Erythematosus, Systemic
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007915
- Subject identifier
- D008180
- Condition identifier
- EFO_0000195
- Highest recorded phase
- 2
- Condition identifier
- HP_0001945
- Condition identifier
- HP_0006767
- Condition identifier
- MONDO_0003210
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004981
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005023
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005113
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005136
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005192
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005249
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005311
- Condition identifier
- MONDO_0005358
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005556
- Condition identifier
- MONDO_0005920
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005921
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008977
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0010911
- Condition identifier
- MONDO_0011382
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018076
- Highest recorded phase
- 1
And 3 more, listed on the interactive page.
- Event
- abdominal discomfort
- Reports
- 1,234
- Reporting signal score
- 2,047.5
- Event
- alopecia
- Reports
- 1,161
- Reporting signal score
- 1,842.69
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 492
- Reporting signal score
- 1,835.16
- Event
- apparent death
- Reports
- 89
- Reporting signal score
- 235.395
- Event
- arthralgia
- Reports
- 1,902
- Reporting signal score
- 2,039.88
- Event
- arthritis
- Reports
- 416
- Reporting signal score
- 509.956
- Event
- arthropathy
- Reports
- 1,142
- Reporting signal score
- 2,589.4
- Event
- blister
- Reports
- 282
- Reporting signal score
- 304.114
- Event
- blood cholesterol increased
- Reports
- 214
- Reporting signal score
- 234.974
- Event
- blood iron abnormal
- Reports
- 158
- Reporting signal score
- 633.854
- Event
- blood parathyroid hormone decreased
- Reports
- 83
- Reporting signal score
- 237.655
- Event
- body height below normal
- Reports
- 67
- Reporting signal score
- 222.709
- Event
- bone density decreased
- Reports
- 101
- Reporting signal score
- 179.053
- Event
- bone erosion
- Reports
- 151
- Reporting signal score
- 443.637
- Event
- breast cancer stage iii
- Reports
- 63
- Reporting signal score
- 214.198
- Event
- c-reactive protein abnormal
- Reports
- 508
- Reporting signal score
- 1,796.78
- Event
- c-reactive protein increased
- Reports
- 571
- Reporting signal score
- 987.336
- Event
- condition aggravated
- Reports
- 1,605
- Reporting signal score
- 1,773.98
- Event
- covid-19
- Reports
- 228
- Reporting signal score
- 177.419
- Event
- disability
- Reports
- 139
- Reporting signal score
- 296.75
- Event
- discomfort
- Reports
- 435
- Reporting signal score
- 739.247
- Event
- diverticulitis
- Reports
- 204
- Reporting signal score
- 242.734
- Event
- drug effective for unapproved indication
- Reports
- 104
- Reporting signal score
- 223.347
- Event
- drug hypersensitivity
- Reports
- 1,267
- Reporting signal score
- 1,087.79
- Event
- drug intolerance
- Reports
- 3,086
- Reporting signal score
- 7,853.92
And 78 more, listed on the interactive page.
- NCT00521924
- NCT01946880
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 28.16
- Calculated partition coefficient (ALogP)
- 4.81
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 24
- Molecular formula
- C18H28Cl3N3
- Monoisotopic mass
- 391.134881
- Natural product
- No
Related records
Trials (141)
- "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"
- A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
- A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
- A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
- A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine
- A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer
- A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands
- A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
- A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh
- A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
- Acceptability and Cost Effectiveness of Home Based Management of Fever: Different Strategies
- ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
- ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
- Adjuvant Effect of Chloroquine on Gemcitabine
- An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
- Antimalarial Drug Resistance in Mali
- Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
- Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia
- Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria
- Assessing a Risk Model for G6PD Deficiency
In development for (2)
- Rheumatoid arthritis Phase 3
- Systemic lupus erythematosus Phase 2